Form 4: Travere Therapeutics Director, Gary A. Lyons, Reports Stock and Option Transactions

Gary A. Lyons, a director at Travere Therapeutics, reported the acquisition of 6,500 shares of common stock and 19,500 stock options on May 8, 2024.

Summary

• On May 8, 2024, Gary A. Lyons, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired automatically under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
• The price of the acquired shares was $0.
• Lyons also acquired 19,500 stock options with an exercise price of $6.82.
• These options vest over a one-year period and expire on May 7, 2034.
• Following these transactions, Lyons beneficially owns 51,000 shares of common stock and 19,500 stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of insider transactions related to compensation.

Positives

• The acquisition of stock and options by a director may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transactions may provide stakeholders with insights into the director's view of the company's value.

Key Dates